scholarly journals Whole-Abdominal Irradiation

2020 ◽  
Author(s):  
Keyword(s):  
Whole Abdominal Irradiation ◽  
Abdominal Irradiation

Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma

1990 ◽  
Vol 36 (3) ◽  
pp. 327-330 ◽  
Author(s):  
David E. Linstadt ◽  
Jeffrey L. Stern ◽  
Jeanne M. Quivey ◽  
Steven A. Leibel ◽  
Conley G. Lacey
Keyword(s):  
Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinoma ◽  
Whole Abdominal Irradiation ◽  
Abdominal Irradiation

Helical Tomotherapy as a New Treatment Technique for Whole Abdominal Irradiation

2008 ◽  
Vol 184 (3) ◽  
pp. 145-149 ◽  
Author(s):  
Nathalie Rochet ◽  
Florian Sterzing ◽  
Alexandra Jensen ◽  
Julien Dinkel ◽  
Klaus Herfarth ◽  
...  
Keyword(s):  
Helical Tomotherapy ◽  
Treatment Technique ◽  
Whole Abdominal Irradiation ◽  
New Treatment ◽  
Abdominal Irradiation

Acute transient radiation hepatitis following whole abdominal irradiation

1976 ◽  
Vol 27 (4) ◽  
pp. 449-454 ◽  
Author(s):  
T.H. Kim ◽  
A.M. Panahon ◽  
M. Friedman ◽  
J.H. Webster
Keyword(s):  
Transient Radiation ◽  
Whole Abdominal Irradiation ◽  
Abdominal Irradiation

Whole Abdominal Irradiation in Non-Hodgkinʼs Lymphomas I. Tolerance and Outcome

1986 ◽  
Vol 9 (5) ◽  
pp. 424-428 ◽  
Author(s):  
Theodore E. Yaeger ◽  
Felipe A. Calvo ◽  
Luther W. Brady
Keyword(s):  
Whole Abdominal Irradiation ◽  
Abdominal Irradiation

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

2006 ◽  
Vol 24 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Marcus E. Randall ◽  
Virginia L. Filiaci ◽  
Hyman Muss ◽  
Nick M. Spirtos ◽  
Robert S. Mannel ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Residual Disease ◽  
Gynecologic Oncology ◽  
Hazard Ratio ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Whole Abdominal Irradiation ◽  
Irradiation Dosage ◽  
To Receive ◽  
Abdominal Irradiation

Purpose To compare whole-abdominal irradiation (WAI) and doxorubicin-cisplatin (AP) chemotherapy in women with stage III or IV endometrial carcinoma having a maximum of 2 cm of postoperative residual disease. Patients and Methods Four hundred twenty-two patients were entered onto this trial. Of 396 assessable patients, 202 were randomly allocated to receive WAI, and 194 were allocated to receive AP. Irradiation dosage was 30 Gy in 20 fractions, with a 15-Gy boost. Chemotherapy consisted of doxorubicin 60 mg/m2 and cisplatin 50 mg/m2 every 3 weeks for seven cycles, followed by one cycle of cisplatin. Results Most patient and tumor characteristics were well balanced. The median patient age was 63 years; 50% had endometrioid tumors. Median follow-up time was 74 months. The hazard ratio for progression adjusted for stage was 0.71 favoring AP (95% CI, 0.55 to 0.91; P < .01). At 60 months, 50% of patients receiving AP were predicted to be alive and disease free when adjusting for stage compared with 38% of patients receiving WAI. The stage-adjusted death hazard ratio was 0.68 (95% CI, 0.52 to 0.89; P < .01) favoring AP. Moreover, at 60 months and adjusting for stage, 55% of AP patients were predicted to be alive compared with 42% of WAI patients. Greater acute toxicity was seen with AP. Treatment probably contributed to the deaths of eight patients (4%) on the AP arm and five patients (2%) on the WAI arm. Conclusion Chemotherapy with AP significantly improved progression-free and overall survival compared with WAI. Nevertheless, further advances in efficacy and reduction in toxicity are clearly needed.

scholarly journals Whole abdominal irradiation for tumors of the uterine corpus

Cancer ◽  
1988 ◽  
Vol 61 (7) ◽  
pp. 1332-1335 ◽  
Author(s):  
Jay S. Loeffler ◽  
Eliot M. Rosen ◽  
Jonathan M. Niloff ◽  
Anthony E. Howes ◽  
Robert C. Knapp
Keyword(s):  
Uterine Corpus ◽  
Whole Abdominal Irradiation ◽  
Abdominal Irradiation
Sign in / Sign up

Export Citation Format

Share Document